

ican Society of Nephrology; Council on Circulation & Renal Section, American Heart Association; International Society for Biochemical Pharmacology; Board of Trustees, Biological Abstracts (Treasurer, 1965-); Drug Research Board, National Academy of Sciences, 1964- ; Editorial Committee, Annual Review of Pharmacology; Editorial Board, Journal of Clinical Pharmacology & Experimental Therapeutics; Committee on Biological Handbooks; National Society for Medical Research Board, 1964- ; Who's Who in America; The Newcomen Society in North America.

AWARDS

The Merck Scientific Award (1959).
The Gairdner Foundation Award (1964).
Modern Pioneers in Creative Industry Award, Natl. Assoc. of Mfgs. (1965).
Modern Medicine's Award for Distinguished Achievement (1967).
American Pharmaceutical Association's Foundation Award in Pharmacodynamics (1967).

OTHER AFFILIATIONS

Lecturer in Physiology: Jefferson Medical College.
Lecturer in Pharmacology: Temple University Medical School.
Lecturer in Pharmacology: Graduate Medical School, University of Pennsylvania.
Special Lecturer in Pharmacology: Woman's Medical College.

PUBLICATIONS (OVER 150 PUBLICATIONS, INCLUDING THESE LISTED)

"Sympathomimetic Amines: The Relation of Structure to Their Action and Inactivation" (Physiol. Rev. 26: 169, 1946).
"Functional Characteristics of Renal Transport Mechanisms" (Pharmacol. Rev. 2: 227, 1950).
"Pharmacological Basis of Penicillin Therapy" (Chas. C. Thomas, Publisher, Springfield, Ill., 1950).
"Factors Basic to the Development of Useful Inhibitors of Renal Transport Mechanisms" (Arch. Int. Pharmacodyn., 98: 97-117 (May) 1954).
"The Mechanism of Action of Chlorothiazide" (Ann. N.Y. Acad. Sci., 71: 363, 1958).
"Newer Diuretics in Progress of Drug Research" (E. Jucker, Ed., Basle, 2, pp. 9-69, 1960).
"Effect of Drugs on Active Transport", in "Enzymes & Drug Action" (Ciba Foundation Symposium, 1962, Ed. J. L. Mongar and A. V. S. deReuck; Pub. by J. & A. Churchill Ltd., London, England.)
"Physiological Basis for the Action of Newer Diuretic Agents" (Pharmacol. Rev. 13: 517-562 (Dec.) 1961).
"Fetal Malformations" (Arch. Env. Health 5: 94-96, 1962).
"The Effect of the New FDA Regulations on the Drug Industry" (Clin. Pharmacol. Therap. 5: 1-5, Jan.-Feb., 1964).
"Method of Inhibiting Gastro-Intestinal Irritation" Patent No. 3,129,137 dated Apr. 14, 1964.
"My Criteria for Acceptable Research in Pharmacology" (Am. J. Pharmaceutical Education 28: No. 5, Dec., 1964).
"Renotropic Characteristics of Ethacrynic Acid; A Phenoxyacetic Saluretic-Diuretic Agent" (J. Pharmacol. Exp. Ther. 147: 1-22, 1965).
"From Theory to Therapy" (Proc. Western Pharmacol. Soc. 8, 1965).
"Perspectives in Toxicology" (Toxicol. & Appl. Pharmacol. 8: No. 1, Jan., 1966).
"The Federation in Midpassage", Introductory Remarks. Fed. Proc. 25: No. 5. Sept.-Oct. 1966.

STATEMENT OF KARL H. BEYER, JR., M.D., PH. D., SENIOR VICE PRESIDENT FOR RESEARCH, MERCK SHARP & DOHME RESEARCH LABORATORIES, DIVISION OF MERCK & CO., INC., RAHWAY, N.J.

Dr. BEYER. Thank you, Senator.

As has been stated by Dr. Tishler, neither the cure for nor the etiology of rheumatoid arthritis is yet within the realm of knowledge of physicians and medical scientists.